Is Medpace Holdings Inc (MEDP) a risky stock?
As of July 24, 2026, Clavix grades Medpace Holdings Inc (MEDP) A- for risk, a composite score of 83 out of 100 on an A+ to F scale, which puts MEDP in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 24, 2026. Clavix regrades every trading day.
The five risk dimensions behind MEDP's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MEDP scores on each, as of July 24, 2026.
What's moving MEDP's risk right now
Company-specific signals Clavix flags behind MEDP's current grade, drawn from recent news and filings as of July 24, 2026.
Medpace posted a stronger-than-expected Q2 and raised its full-year outlook, while bookings also topped estimates, reversing earlier weakness. The 18.6% stock jump reflects renewed confidence in demand for its clinical rating services.
Medpace issued 2026 GAAP EPS guidance of $17.25-$17.95 on revenue of $2.805-$2.885 billion, with the EPS range landing above rating consensus. Management signals stronger profits even as the revenue range matches prior expectations.
Recent MEDP news
The latest headlines Clavix ingested for Medpace Holdings Inc, newest first. These feed the news-sentiment dimension of MEDP's grade.
What a A- grade means
On the Clavix A+ to F scale, MEDP's composite of 83 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MEDP or any security. Grades are risk indicators, not predictions of return. Data may be delayed.